 |
市场调查报告书
商品编码
1773136
MSL 指标：衡量成功的整体方法MSL Metrics: A Holistic Approach to Measuring Success |
||||||
本报告深入探讨了製药业医学科学联络（MSL）指标的复杂性，并对用于评估 MSL 绩效的定量和定性指标进行了全面分析。报告强调了製定符合策略业务目标并推动利害关係人参与的有效指标所面临的挑战和机会。将深入了解混合工作模式对 MSL 活动的影响、数位平台在指标收集中的作用，以及将指标置于具体情境中以反映 MSL 的真正价值的重要性。本报告也探讨了第三方基准测试的潜在优势和局限性，并强调了医学事务团队在领导指标制定和沟通方面的关键作用。对于寻求最佳化 MSL 绩效评估并将其融入更广泛的组织策略的製药专业人士来说，这份资源非常重要。
关键问题
- 1.目前使用哪些定量和定性指标来评估 MSL 绩效？
- 2.MSL 如何看待这些指标的有效性和相关性？
- 3.公司在製定和采用有意义的MSL 指标方面面临哪些挑战？
- 4.新冠疫情后向混合工作模式的转变对 MSL 敬业度指标有何影响？
- 5.MSL 在指标的选择与采用上扮演什么角色？
- 6.公司如何将 MSL 指标与更广泛的医疗事务和商业策略结合？
- 7.使用第三方 MSL 绩效基准测试的潜在优点和缺点是什么？
- 8.除了量化指标之外，如何制定定性指标来捕捉 MSL 的更广泛影响？
- 9.数位平台在收集和呈现 MSL 指标方面可以发挥什么作用？
- 10.医疗事务团队如何在其组织内引领 MSL 指标的情境化与沟通？
主要公司
|
|
部分参与专家名单
- 总部位于法国的製药公司的MSL
- 德国BioMarin製药公司资深MSL
- 义大利一家生物製药公司的医学科学主管
- 西班牙一家2024年全球销售额排名前20的製药公司的高级MSL
- 英国GSK的MSL
- 美国Teva Pharmaceuticals全球医学合作副总裁
方法论：
调查报告是基于独立而简洁的分析，这些分析源自于专有的产业研究以及对产业意见领袖的深入访谈。报告深入分析了製药公司高层需要了解的关键趋势和市场发展，以应对未来的机会和挑战。每份报告的重点都透过对二手文献的回顾和已识别的知识差距来确定。基于这些初步研究，创建了基于证据、专家指导的讨论指南，以确保调查能回答最重要的问题。此外，制定了严格的筛选标准，以确保受访者有足够的经验、知识和资格就相关主题发表意见。
报告有何特别之处？
FirstWord Reports 是值得信赖的行业领导者，致力于製药业，为生物製药专业人士和决策者提供详尽且切实可行的洞察。深厚的行业知识使能够提供相关且有价值的洞察，帮助掌握新兴趋势，有效应对复杂挑战。凭藉广泛的研究以及来自顶尖专家和关键意见领袖（KOL）的独立、公正的见解，报告能够提供所需的准确性和可靠性。独家获取其他地方无法获得的采访和资料，以及持续的市场监测，让全面了解市场动态。报告涵盖 40 多个活跃的疾病领域，提供包括关键意见领袖洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入和其他领域问题的看法，使能够做出更明智的资料驱动决策，在快速变化的行业中保持竞争力。
This report delves into the intricacies of Medical Science Liaison (MSL) metrics within the pharmaceutical industry, providing a comprehensive analysis of both quantitative and qualitative measures used to evaluate MSL performance. It addresses the challenges and opportunities in developing meaningful metrics that align with strategic business goals and enhance stakeholder engagement. Gain insights into the impact of hybrid working models on MSL activities, the role of digital platforms in metric collection and the importance of contextualising metrics to reflect the true value of MSLs. The report also explores the potential benefits and limitations of third-party benchmarking and highlights the critical role of medical affairs teams in leading metric development and communication. This resource is essential for pharmaceutical professionals seeking to optimise MSL performance evaluation and integration into broader organisational strategies.
Key Questions Answered:
- 1. What are the current quantitative and qualitative metrics used to evaluate MSL performance?
- 2. How do MSLs perceive the effectiveness and relevance of these metrics?
- 3. What challenges do companies face in developing and implementing meaningful MSL metrics?
- 4. How has the shift to hybrid working models post-COVID-19 impacted MSL engagement metrics?
- 5. What role do MSLs play in shaping the choice and application of metrics?
- 6. How can companies ensure that MSL metrics align with broader medical affairs and business strategies?
- 7. What are the potential benefits and drawbacks of using third-party benchmarking for MSL performance?
- 8. How can qualitative metrics be developed to capture the broader impact of MSLs beyond quantitative measures?
- 9. What is the role of digital platforms in collecting and presenting MSL metrics?
- 10. How can medical affairs teams lead in the contextualisation and communication of MSL metrics within the organisation?
Key Companies:
|
|
Partial List of Participating Experts:
- An MSL at a pharmaceutical company, based in France.
- A Senior MSL at BioMarin Pharmaceutical, based in Germany.
- A Medical Science Lead at a biopharmaceutical company, based in Italy.
- A Senior MSL at a pharmaceutical company in the top 20 by global sales in 2024, based in Spain.
- MSL at GSK, based in the UK.
- Global Vice President, Medical Engagement at Teva Pharmaceuticals, based in the US
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
